{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-020816","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.236833+00:00","generated_at":"2026-05-17T00:20:09.959324+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg","bullets":["October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.","Medical practices with multiple CyPath orders rose 106% QoQ in Q3 and 67% in Oct vs YTD monthly avg.","CyPath Lung noninvasive sputum test uses AI/flow cytometry; clinical study showed 92% sensitivity, 87% specificity.","CEO Maria Zannes cites growing physician trust and successful outreach to pulmonologists, health systems, VA centers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-020816","json":"https://secwatch.observer/filing/0001493152-25-020816.json","markdown":"https://secwatch.observer/filing/0001493152-25-020816.md","text":"https://secwatch.observer/filing/0001493152-25-020816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/0001493152-25-020816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225020816/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:20:09.959324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}